NCT07574645 Spinal Dural Arteriovenous Fistula International Data and Outcomes Registry
| NCT ID | NCT07574645 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Thomas Jefferson University |
| Condition | Spinal Dural Arteriovenous Fistula |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2026-01-05 |
| Primary Completion | 2026-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2026-01-05 with a primary completion date of 2026-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Given the lack of large multicenter datasets in the context of Spinal arteriovenous fistula, the strength of the evidence surrounding this rare disease is limited. SPIDER hence aims to address that by compiling patient-level data from centers all around the world.
Eligibility Criteria
Inclusion Criteria: * Type 1 spinal dural arteriovenous fistula, confirmed on imaging * Surgically or endovascularly treated * At least 1 available primary outcome
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07574645 clinical trial?
This trial is open to participants of all sexes, studying Spinal Dural Arteriovenous Fistula. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07574645 currently recruiting?
Yes, NCT07574645 is actively recruiting participants. Contact the research team at pascal.jabbour@jefferson.edu for enrollment information.
Where is the NCT07574645 trial being conducted?
This trial is being conducted at Philadelphia, United States.
Who is sponsoring the NCT07574645 clinical trial?
NCT07574645 is sponsored by Thomas Jefferson University. The trial plans to enroll 1,000 participants.